Evidence map›Paper›PMID 36939853›Full record

ArticleCancer immunology, immunotherapy : CII2023

Establishment of a novel NFAT-GFP reporter platform useful for the functional avidity maturation of HLA class II-restricted TCRs.

Fumihiro Fujiki, Soyoko Morimoto, Yuya Nishida, Satoe Tanii, Nao Aoyama, Miki Inatome, Kento Inoue, Akiko Katsuhara, Hiroko Nakajima, Jun Nakata and 6 more

Open access · hybridAbstract read
In one paragraph

Article in Cancer immunology, immunotherapy : CII, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.2field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 citations in OpenAlex.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 2 institutions in 1 country.

Fumihiro FujikiDepartment of Cancer Immunology, Osaka University Graduate School of Medicine, Suita, Osaka, 565-0871, Japan. fu-fuji@sahs.med.osaka-u.ac.jp.
Soyoko MorimotoDepartment of Cancer Stem Cell Biology, Osaka University Graduate School of Medicine, Suita, Japan.
Yuya NishidaDepartment of Clinical Laboratory and Biomedical Sciences, Osaka University Graduate School of Medicine, Suita, Japan.
Satoe TaniiDepartment of Functional Diagnostic Science, Osaka University Graduate School of Medicine, Suita, Japan.
Nao AoyamaDepartment of Functional Diagnostic Science, Osaka University Graduate School of Medicine, Suita, Japan.
Miki InatomeDepartment of Functional Diagnostic Science, Osaka University Graduate School of Medicine, Suita, Japan.
Kento InoueDepartment of Clinical Laboratory and Biomedical Sciences, Osaka University Graduate School of Medicine, Suita, Japan.
Akiko KatsuharaDepartment of Functional Diagnostic Science, Osaka University Graduate School of Medicine, Suita, Japan.
Hiroko NakajimaDepartment of Cancer Immunology, Osaka University Graduate School of Medicine, Suita, Osaka, 565-0871, Japan.
Jun NakataDepartment of Clinical Laboratory and Biomedical Sciences, Osaka University Graduate School of Medicine, Suita, Japan.
Sumiyuki NishidaStrategic Global Partnership & X (Cross)-Innovation Initiative, Graduate School of Medicine, Osaka University & Osaka University Hospital, Suita, Japan.
Akihiro TsuboiDepartment of Cancer Immunotherapy, Osaka University Graduate School of Medicine, Suita, Osaka, 565-0871, Japan.
Yoshihiro OkaDepartment of Cancer Stem Cell Biology, Osaka University Graduate School of Medicine, Suita, Japan.
Yusuke OjiDepartment of Clinical Laboratory and Biomedical Sciences, Osaka University Graduate School of Medicine, Suita, Japan.
Shinji SogoDepartment of Cancer Immunology, Osaka University Graduate School of Medicine, Suita, Osaka, 565-0871, Japan.
Haruo SugiyamaDepartment of Cancer Immunology, Osaka University Graduate School of Medicine, Suita, Osaka, 565-0871, Japan.
The University of Osaka · JPOtsuka (Japan) · JP

Funding

Japan Society for the Promotion of Science 17K07215Japan Society for the Promotion of Science 17K07216Japan Society for the Promotion of Science 19K07729
6 · The paper itself

Abstract

CD4

Indexed as

Immunotherapy, AdoptiveNeoplasmsAntigens, NeoplasmCD4-Positive T-LymphocytesHumansReceptors, Antigen, T-CellAntigens, NeoplasmReceptors, Antigen, T-CellCD4+ T cellHLA class IINFAT-GFP reporterTCRTCR-T therapyWT1

Identifiers

PMID36939853
PMCPMC10264488
OpenAlexW4327902045

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.